Clinical Trial Update: BIBW 2992 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for afatinib (BIBW 2992) in patients with advanced solid tumors; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED